HER2-Orientated Therapy in Early and Metastatic Breast Cancer.

Breast Care (Basel) 2016 Dec 8;11(6):392-397. Epub 2016 Dec 8.

Department of Gynecology and Obstetrics, University Medical Center Aachen, Aachen, Germany.

Due to the enhanced understanding of molecular oncology and signaling pathways in breast cancer (BC), therapy management has undergone a major transformation, especially with the emergence of treatment tailored to individual disease characteristics. In the case of HER2-positive early or metastatic BC, targeted therapies are well established and remain a major focus of ongoing research. The introduction of anti-HER2 biologicals such as trastuzumab, pertuzumab, and T-DM1 has made targeted and personalized treatment possible and has clearly improved disease-free and overall survival in patients with HER2-positive BC. Moreover, neoadjuvant chemotherapy represents a well-established and often favored option for patients with operable BC and a clear indication for postoperative chemotherapy (such as HER2-positive BC). Other trials are trying to identify additional surrogate markers for therapy response and clinical outcome in the neoadjuvant setting and that way open up new perspectives with a possible de-escalation of classical treatment in favor of targeted therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000453603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290438PMC
December 2016
13 Reads

Publication Analysis

Top Keywords

breast cancer
8
early metastatic
8
anti-her2 biologicals
4
surrogate markers
4
markers therapy
4
introduction anti-her2
4
biologicals trastuzumab
4
additional surrogate
4
identify additional
4
t-dm1 targeted
4
pertuzumab t-dm1
4
trastuzumab pertuzumab
4
ongoing introduction
4
therapy response
4
therapies well
4
targeted therapies
4
outcome neoadjuvant
4
metastatic targeted
4
well established
4
response clinical
4

Similar Publications